Evolent Health (NYSE:EVH) Stock Gets Price Target Boost from Oppenheimer

Key Points

• Oppenheimer raised its price target on Evolent Health from $6 to $7 and maintained an “outperform” rating, implying 51.35% upside from the share price cited in the report.
• Analyst views are mixed but lean positive: MarketBeat reports a “Moderate Buy” consensus and an average price target of $6.11, based on 11 Buy, four Hold, and one Sell rating.
• Quarterly EPS of $0.06 matched expectations, while revenue rose 51.3% year over year to $725.37 million but came in slightly below forecasts. The company continued to report a negative net margin and negative return on equity.

Evolent Health (NYSE:EVH - Get Free Report) had its price target boosted by investment analysts at Oppenheimer from $6.00 to $7.00 in a report issued on Friday, Benzinga reports. The firm presently has an "outperform" rating on the technology company's stock. Oppenheimer's price target would indicate a potential upside of 51.35% from the company's current price.

Several other research firms also recently commented on EVH. Weiss Ratings downgraded shares of Evolent Health from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, October 16th. Truist Financial cut their price objective on Evolent Health from $7.00 to $6.00 and set a "hold" rating for the company in a research report on Wednesday, August 12th. Canaccord Genuity Group decreased their price target on Evolent Health from $7.00 to $6.00 and set a "buy" rating on the stock in a research note on Monday, August 10th. TD Cowen lifted their price objective on Evolent Health from $5.00 to $6.00 and gave the stock a "buy" rating in a report on Monday, August 17th. Finally, Citigroup upgraded Evolent Health from a "neutral" rating to a "buy" rating and decreased their target price for the stock from $6.75 to $6.00 in a research report on Monday, August 10th. Eleven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $6.11.

Evolent Health Trading Up 1.9%

Evolent Health stock traded up $0.09 during mid-day trading on Friday, hitting $4.62. The company's stock had a trading volume of 820,560 shares, compared to its average volume of 2,833,896. The firm has a market capitalization of $522.90 million, a PE ratio of -1.01 and a beta of 1.03. Evolent Health has a 1 year low of $2.10 and a 1 year high of $6.28. The company has a current ratio of 1.24, a quick ratio of 1.24 and a debt-to-equity ratio of 2.52. The stock's fifty day moving average is $4.17 and its two-hundred day moving average is $3.88.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The technology company reported $0.06 earnings per share for the quarter, meeting analysts' consensus estimates of $0.06. The business had revenue of $725.37 million during the quarter, compared to analysts' expectations of $727.06 million. Evolent Health had a negative net margin of 24.08% and a negative return on equity of 4.27%. The business's revenue for the quarter was up 51.3% on a year-over-year basis. During the same period last year, the business earned $0.05 earnings per share. On average, analysts anticipate that Evolent Health will post -0.25 EPS for the current year.

Insider Buying and Selling at Evolent Health

In other news, President Daniel Mccarthy sold 65,892 shares of the company's stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $5.00, for a total transaction of $329,460.00. Following the completion of the sale, the president directly owned 655,133 shares in the company, valued at $3,275,665. This represents a 9.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.48% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Evolent Health

A number of institutional investors and hedge funds have recently bought and sold shares of EVH. First Trust Advisors LP bought a new stake in shares of Evolent Health during the 1st quarter worth about $488,000. Public Employees Retirement System of Ohio bought a new position in shares of Evolent Health in the second quarter valued at approximately $760,000. Sei Investments Co. boosted its holdings in shares of Evolent Health by 50.8% in the first quarter. Sei Investments Co. now owns 302,281 shares of the technology company's stock valued at $689,000 after acquiring an additional 101,867 shares in the last quarter. Corient Private Wealth LP increased its stake in shares of Evolent Health by 447.4% during the second quarter. Corient Private Wealth LP now owns 81,594 shares of the technology company's stock valued at $442,000 after acquiring an additional 66,687 shares during the period. Finally, Congress Asset Management Co. increased its stake in shares of Evolent Health by 20.3% during the third quarter. Congress Asset Management Co. now owns 275,158 shares of the technology company's stock valued at $960,000 after acquiring an additional 46,466 shares during the period.

Trending Headlines about Evolent Health

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Needham raised its price target to $6 from $5 and maintained a Buy rating, implying about 31% upside from the cited $4.58 share price. Needham analyst rating
• Positive Sentiment: Management’s FY 2026 revenue outlook is $2.6 billion–$2.7 billion. The upper end is above the roughly $2.6 billion analyst consensus, though the range’s midpoint is close to expectations.
• Positive Sentiment: Q3 revenue grew 51.3% year over year to $725.37 million, and EPS of $0.06 matched consensus and exceeded the year-ago $0.05. The company also said customers are renewing and, in many cases, expanding their work with Evolent. Q3 results
• Negative Sentiment: Revenue came in slightly below analysts’ $727.06 million estimate. The reported negative net margin and negative return on equity also underline ongoing profitability challenges.

Evolent Health Company Profile

Evolent Health, Inc NYSE: EVH is a healthcare services and technology company that helps health plans and healthcare providers transition to value-based care. Its platform is designed to support the management of clinical programs, improve patient outcomes and coordinate care while helping customers manage healthcare costs.

The company provides specialty and total-cost-of-care solutions across areas such as cardiology, oncology, musculoskeletal care, radiology and other complex conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.